Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA.

J Clin Oncol. 2011 Mar 1;29(7):917-24. doi: 10.1200/JCO.2010.32.2537. Epub 2011 Jan 31.

2.

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD.

Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Epub 2011 Apr 5. Review.

3.
4.

Vaccination for malignant melanoma: recent developments.

Jäger D, Jäger E, Knuth A.

Oncology. 2001;60(1):1-7. Review.

PMID:
11150901
5.

Immunotherapy for the management of advanced melanoma: the next steps.

Zikich D, Schachter J, Besser MJ.

Am J Clin Dermatol. 2013 Aug;14(4):261-72. doi: 10.1007/s40257-013-0013-0. Review.

PMID:
23516145
6.

Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

Rosenberg SA.

Nat Rev Clin Oncol. 2011 Aug 2;8(10):577-85. doi: 10.1038/nrclinonc.2011.116. Review.

PMID:
21808266
8.

Exploiting the curative potential of adoptive T-cell therapy for cancer.

Hinrichs CS, Rosenberg SA.

Immunol Rev. 2014 Jan;257(1):56-71. doi: 10.1111/imr.12132. Review.

9.

Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Shah DJ, Dronca RS.

Mayo Clin Proc. 2014 Apr;89(4):504-19. doi: 10.1016/j.mayocp.2014.02.002. Review.

10.

Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors.

Fujiwara H.

Pharmaceuticals (Basel). 2014 Dec 15;7(12):1049-68. doi: 10.3390/ph7121049. Review.

11.

Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy.

Lee N, Zakka LR, Mihm MC Jr, Schatton T.

Pathology. 2016 Feb;48(2):177-87. doi: 10.1016/j.pathol.2015.12.006. Epub 2016 Jan 16. Review.

PMID:
27020390
12.

Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines.

Vreeland TJ, Clifton GT, Herbert GS, Hale DF, Jackson DO, Berry JS, Peoples GE.

Expert Rev Clin Immunol. 2016 Dec;12(12):1347-1357. Epub 2016 Jun 28. Review.

PMID:
27323245
13.

Immunotherapy of distant metastatic disease.

Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P.

Ann Oncol. 2009 Aug;20 Suppl 6:vi41-50. doi: 10.1093/annonc/mdp253. Review.

14.

Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.

Nowicki TS, Anderson JL, Federman N.

Pediatr Res. 2016 Mar;79(3):371-7. doi: 10.1038/pr.2015.246. Epub 2015 Nov 23. Review.

PMID:
26595537
15.

Interface of signal transduction inhibition and immunotherapy in melanoma.

Shada AL, Molhoek KR, Slingluff CL Jr.

Cancer J. 2010 Jul-Aug;16(4):360-6. doi: 10.1097/PPO.0b013e3181eb3393. Review.

16.

Immunotherapy of Melanoma.

Bender C, Hassel JC, Enk A.

Oncol Res Treat. 2016;39(6):369-76. doi: 10.1159/000446716. Epub 2016 May 25. Review.

PMID:
27259558
17.

In-situ tumor vaccination: Bringing the fight to the tumor.

Pierce RH, Campbell JS, Pai SI, Brody JD, Kohrt HE.

Hum Vaccin Immunother. 2015;11(8):1901-9. doi: 10.1080/21645515.2015.1049779. Review.

18.

Metastatic biomarkers in synovial sarcoma.

de Necochea-Campion R, Zuckerman LM, Mirshahidi HR, Khosrowpour S, Chen CS, Mirshahidi S.

Biomark Res. 2017 Feb 7;5:4. doi: 10.1186/s40364-017-0083-x. eCollection 2017. Review.

19.

NGcGM3/VSSP vaccine as treatment for melanoma patients.

Pérez K, Osorio M, Hernández J, Carr A, Fernández LE.

Hum Vaccin Immunother. 2013 Jun;9(6):1237-40. doi: 10.4161/hv.24115. Epub 2013 Feb 26. Review.

20.

Tumor-Infiltrating Lymphocyte Therapy and Neoantigens.

Robbins PF.

Cancer J. 2017 Mar/Apr;23(2):138-143. doi: 10.1097/PPO.0000000000000267. Review.

PMID:
28410302

Supplemental Content

Support Center